Roche’s Risdiplam Showed Significant Improvement in Motor Function in People who have SMA Type 2 or 3
06 February 2020
Roche today presented 1-year data, at the 2nd International Scientific and Clinical Congress on SMA in Evry, France, from the pivotal Part 2 of their SUNFISH trial - a global placebo-controlled study evaluating risdiplam in people aged 2-25 years who have SMA Type 2 or 3.
The study showed that the change from baseline in the primary endpoint of the Motor Function Measure scale was significantly greater in people treated with risdiplam, compared to the placebo. The Revised Upper Limb Module also showed an improvement.